Epidemiology and clinical characteristics of viral infections in hospitalized children and adolescents with cancer in Lebanon.
Adolescent
Child
Child, Hospitalized
Child, Preschool
Coinfection
/ complications
Cytomegalovirus Infections
/ complications
Female
Hematopoietic Stem Cell Transplantation
Hospitals
Humans
Infant
Influenza, Human
/ complications
Lebanon
/ epidemiology
Multiplex Polymerase Chain Reaction
/ methods
Neoplasms
/ complications
Pediatrics
Respiratory Syncytial Virus, Human
/ genetics
Respiratory Tract Infections
/ complications
Retrospective Studies
Rotavirus Infections
/ complications
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
11
2019
accepted:
02
09
2020
entrez:
22
9
2020
pubmed:
23
9
2020
medline:
5
11
2020
Statut:
epublish
Résumé
Viral infections in children and adolescents with malignancy are commonly encountered and have a significant impact on morbidity and mortality. Studies and epidemiological data regarding viral infections in children with cancer in developing countries are lacking. This retrospective cohort study aims to assess the burden of viral infections in children and adolescents with cancer, by assessing prevalence, risk factors, as well as morbidity and mortality of common viruses over a period of 8 years. Medical records of cancer patients treated at the Children Cancer Center of Lebanon were reviewed and 155 participants under the age of 21 were identified with at least one documented viral infection during the period from July 2009 to November 2017. This subset included 136 participants with active malignancy and 19 participants with a history of cancer who underwent hematopoietic stem cell transplantation [HSCT] and were in remission; the latter group was analyzed separately. Information regarding participant characteristics, hospital course, and complications were obtained. Associations between viral infections and certain factors were assessed. In the cohort, 64% were male, 81% were Lebanese. In participants with active malignancy, 90% received chemotherapy in the 6 months preceding the viral infection episode, 11% received radiotherapy. 51% of participants were neutropenic at the time of viral detection, and 77% were lymphopenic. 17% experienced a bacterial co-infection, and 3 experienced a viral co-infection. Among 162 viral infection episodes, clinically diagnosed skin infections, mainly herpes simplex virus type 1 and varicella-zoster virus, were the most common [44% of cases]. These were followed by laboratory-proven systemic herpes infections: cytomegalovirus [14%] and Epstein-Barr virus [6%]. Respiratory viruses: influenza and respiratory syncytial virus, accounted for 9% and 4%, respectively, whereas rotavirus represented 11% and BK virus represented 3% of cases. Acute lymphocytic leukemia was the most prevalent neoplasia [57%]. Fever was the most common presenting symptom [55%] and febrile neutropenia was the reason for admission in 24% of cases. The mean length of stay was significantly longer in participants with cytomegalovirus infections and significantly lower in rotavirus infection. Admission to the ICU occurred in 9%, complications in 8%, and mortality in 5%. Participants with viral infections post-HSCT were noted to have a significantly longer length of hospital stay compared to non-HSCT participants, with no other significant differences in clinical course and outcome. The study was limited by its retrospective nature and by the late introduction and underuse of multiplex PCR panels, which may have led to underdiagnosis of viral infections. Viral infections were prevalent in our sample of cancer patients and may have contributed to morbidity and mortality. Newly available viral diagnostics are likely to vastly increase the number and scope of detectable viral infections in this population. Prospective studies using multiplex PCR technology with systematic testing of patients will be more helpful in defining the burden of viral infections. Furthermore, efforts at antimicrobial stewardship would benefit from the identification of viral causes of infection and limit the unnecessary use of antibiotics in the pediatric cancer population.
Sections du résumé
BACKGROUND
Viral infections in children and adolescents with malignancy are commonly encountered and have a significant impact on morbidity and mortality. Studies and epidemiological data regarding viral infections in children with cancer in developing countries are lacking. This retrospective cohort study aims to assess the burden of viral infections in children and adolescents with cancer, by assessing prevalence, risk factors, as well as morbidity and mortality of common viruses over a period of 8 years.
METHODS AND FINDINGS
Medical records of cancer patients treated at the Children Cancer Center of Lebanon were reviewed and 155 participants under the age of 21 were identified with at least one documented viral infection during the period from July 2009 to November 2017. This subset included 136 participants with active malignancy and 19 participants with a history of cancer who underwent hematopoietic stem cell transplantation [HSCT] and were in remission; the latter group was analyzed separately. Information regarding participant characteristics, hospital course, and complications were obtained. Associations between viral infections and certain factors were assessed. In the cohort, 64% were male, 81% were Lebanese. In participants with active malignancy, 90% received chemotherapy in the 6 months preceding the viral infection episode, 11% received radiotherapy. 51% of participants were neutropenic at the time of viral detection, and 77% were lymphopenic. 17% experienced a bacterial co-infection, and 3 experienced a viral co-infection. Among 162 viral infection episodes, clinically diagnosed skin infections, mainly herpes simplex virus type 1 and varicella-zoster virus, were the most common [44% of cases]. These were followed by laboratory-proven systemic herpes infections: cytomegalovirus [14%] and Epstein-Barr virus [6%]. Respiratory viruses: influenza and respiratory syncytial virus, accounted for 9% and 4%, respectively, whereas rotavirus represented 11% and BK virus represented 3% of cases. Acute lymphocytic leukemia was the most prevalent neoplasia [57%]. Fever was the most common presenting symptom [55%] and febrile neutropenia was the reason for admission in 24% of cases. The mean length of stay was significantly longer in participants with cytomegalovirus infections and significantly lower in rotavirus infection. Admission to the ICU occurred in 9%, complications in 8%, and mortality in 5%. Participants with viral infections post-HSCT were noted to have a significantly longer length of hospital stay compared to non-HSCT participants, with no other significant differences in clinical course and outcome. The study was limited by its retrospective nature and by the late introduction and underuse of multiplex PCR panels, which may have led to underdiagnosis of viral infections.
CONCLUSIONS
Viral infections were prevalent in our sample of cancer patients and may have contributed to morbidity and mortality. Newly available viral diagnostics are likely to vastly increase the number and scope of detectable viral infections in this population. Prospective studies using multiplex PCR technology with systematic testing of patients will be more helpful in defining the burden of viral infections. Furthermore, efforts at antimicrobial stewardship would benefit from the identification of viral causes of infection and limit the unnecessary use of antibiotics in the pediatric cancer population.
Identifiants
pubmed: 32961548
doi: 10.1371/journal.pone.0239258
pii: PONE-D-19-32741
pmc: PMC7508634
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0239258Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer. 2016 Mar 1;122(5):798-805
pubmed: 26700662
J Clin Microbiol. 2016 Nov;54(11):2635-2646
pubmed: 27280421
J Pathol. 2015 Jan;235(2):288-97
pubmed: 25205255
Medicine (Baltimore). 1985 Mar;64(2):100-14
pubmed: 2983175
Clin Lab Med. 2015 Jun;35(2):461-86
pubmed: 26004652
Bone Marrow Transplant. 2008 Jan;41(1):11-8
pubmed: 17952131
J Pediatr Hematol Oncol. 2018 Nov;40(8):605-608
pubmed: 30188350
J Clin Virol. 2010 Mar;47(3):234-7
pubmed: 20056482
Clin Infect Dis. 2005 Aug 1;41(3):354-60
pubmed: 16007533
Prz Gastroenterol. 2017;12(1):68-69
pubmed: 28337241
Pediatr Blood Cancer. 2008 May;50(5):983-7
pubmed: 18240170
Pediatrics. 1987 Oct;80(4):465-72
pubmed: 2821476
Pediatr Blood Cancer. 2010 Jan;54(1):79-82
pubmed: 19743304
Ann Oncol. 2017 Feb 1;28(2):400-407
pubmed: 27831506
Clin Lymphoma Myeloma. 2006 Mar;6(5):393-8
pubmed: 16640816
Klin Padiatr. 2005 Nov;217 Suppl 1:S67-84
pubmed: 16288353
Biol Blood Marrow Transplant. 2008 Aug;14(8):867-71
pubmed: 18640569
BMC Infect Dis. 2018 Jun 28;18(1):289
pubmed: 29954328
Clin Infect Dis. 2011 Feb 15;52(4):e56-93
pubmed: 21258094
J Pediatr Hematol Oncol. 2009 Sep;31(9):623-9
pubmed: 19644403
Br J Dermatol. 1975 Jun;92(6):625-30
pubmed: 1101940
Pediatr Rev. 2016 Jun;37(6):247-58
pubmed: 27252180
Pediatr Rep. 2011 Feb 24;3(1):e5
pubmed: 21647278
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
J Med Virol. 2019 Jul;91(7):1191-1201
pubmed: 30763464
J Pediatr Hematol Oncol. 2012 Aug;34(6):442-9
pubmed: 22767134
Scand J Gastroenterol. 2007 Jan;42(1):81-7
pubmed: 17190767
Cancer Lett. 2014 Jan 1;342(1):1-8
pubmed: 24041869
Bone Marrow Transplant. 2011 Jan;46(1):119-24
pubmed: 20228849
Semin Hematol. 2009 Jul;46(3):313-24
pubmed: 19549582
PLoS One. 2018 Mar 22;13(3):e0194009
pubmed: 29565992
J Microbiol Immunol Infect. 2011 Dec;44(6):442-8
pubmed: 21602111
Front Microbiol. 2018 Dec 12;9:3097
pubmed: 30619176
Pediatr Blood Cancer. 2005 Dec;45(7):945-51
pubmed: 16047356
Pediatrics. 2008 Feb;121(2):235-43
pubmed: 18245413
Cancer. 1995 Apr 1;75(7):1712-7
pubmed: 8826932
Infect Dis Ther. 2017 Mar;6(1):69-83
pubmed: 28160269
Pediatr Infect Dis J. 2016 Sep;35(9):949-54
pubmed: 27518750
Support Care Cancer. 2006 Mar;14(3):277-84
pubmed: 16270193
Clin Microbiol Rev. 2011 Jan;24(1):193-209
pubmed: 21233512
Exp Ther Med. 2018 Jun;15(6):4805-4809
pubmed: 29805499
Obstet Gynecol. 1998 Oct;92(4 Pt 2):642-4
pubmed: 9764645
World J Pediatr. 2016 Aug;12(3):320-326
pubmed: 27351567